Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2021

$3,495.00

The Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies.

Publication date
April 2021
Number of pages
300+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP2050

The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies.

 

This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report covers details of co-promotion and co-marketing agreements from 2014 to 2021.

 

For pharmaceutical and biotechnology professionals, the report supplies a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of all co-promotion and co-marketing deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of co-promotion and co-marketing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of each type of deal.

 

Chapters 3 and 4 provide an overview of the structure of co-promotion and co-marketing deals, respectively. Each chapter includes numerous case studies to enable understanding of both pure co-promotion/marketing deals and multicomponent deals where co-promotion/marketing forms a part.

 

Chapter 5 provides a review of the leading co-promotion and co-marketing deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

 

Chapter 6 provides a review of the top 25 most active biopharma companies in co-promotion and co-marketing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

 

Chapter 7 provides a comprehensive and detailed review of co-promotion and co-marketing deals signed and announced since 2014 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

 

The report also includes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing deal making since 2014.

 

In addition, a comprehensive appendix is provided organized by co-promotion and co-marketing company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about co-promotion and co-marketing partnering in the research, development and commercialization of technologies and products.

 

Key benefits

 

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides the reader with the following key benefits:

 

  • In-depth understanding of co-promotion and co-marketing deal trends since 2014
  • Analysis of the structure of co-promotion and co-marketing agreements with numerous real life case studies
  • Comprehensive access to over 350 actual co-promotion and co-marketing deals entered into by the world’s biopharma companies
  • Insight into the terms included in a co-promotion and co-marketing agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report is intended to provide the reader with an in-depth understanding of the co-promotion and co-marketing trends and structure of deals entered into by leading biopharma companies worldwide.

 

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 includes:

 

  • Trends in co-promotion and co-marketing dealmaking in the biopharma industry since 2014
  • Analysis of co-promotion and co-marketing deal structure
  • Case studies of real-life co-promotion and co-marketing deals
  • Access to over 350 co-promotion and co-marketing deal records
  • Detailed access to actual co-promotion contract documents
  • The leading co-promotion and co-marketing deals by value since 2014
  • Most active co-promotion and co-marketing dealmakers since 2014
  • The leading co-promotion and co-marketing partnering resources

 

In Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021, the available contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Therapeutic area
  • Technology area

 

Each deal title links via Weblink to an online version of deal record as found in the Current Agreements deals and alliances database, providing easy access to each deal record on demand.

 

The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive access to records for over 350 co-promotion and co-marketing deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise co-promotion and co-marketing rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2021 provides the reader with the following key benefits:

 

  • In-depth understanding of co-promotion and co-marketing deal trends since 2014
  • Analysis of the structure of co-promotion and co-marketing agreements with numerous real life case studies
  • Comprehensive access to over 350 co-promotion and co-marketing deals entered into by the world’s biopharma companies, together with contract documents if available
  • Detailed access to actual co-promotion and co-marketing contracts entered into by the leading big pharma and big biotech companies
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
  • Identify leading co-promotion and co-marketing deals by value since 2014
  • Identify the most active co-promotion and co-marketing dealmakers since 2014
  • Full listing of co-promotion and co-marketing deals by company A-Z, headline value, phase of development, deal type, therapy and technology focus

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in co-promotion and co-marketing dealmaking

 

2.1. Introduction

2.2. Difference between co-promotion and co-marketing deals

2.3. Trends in co-promotion deals since 2014

2.3.1. Co-promotion and co-marketing dealmaking by year, 2014 to 2021

2.3.2. Co-promotion and co-marketing dealmaking by phase of development, 2014 to 2021

2.3.3. Co-promotion and co-marketing dealmaking by industry sector, 2014 to 2021

2.3.4. Co-promotion and co-marketing dealmaking by therapy area, 2014 to 2021

2.3.5. Co-promotion and co-marketing dealmaking by technology type, 2014 to 2021

2.3.6. Co-promotion and co-marketing dealmaking by most active company, 2014 to 2021

2.4. When co-marketing can be useful

2.5. When co-marketing is the only option

2.6. Pure deals and multi-component deals

2.6.1. Attributes of pure co-promotion deals

2.6.2. Attributes of co-promotion in multi-component deals

2.7. Reasons for including co-promotion options in a deal

2.8. Uptake of co-promotion rights

2.9. Co-promotion rights as bargaining chips

2.10. Aligning partners to make the co-promote work

2.11. The future of co-promotion as part of multicomponent deals

 

Chapter 3 – Overview of co-promotion deal structure

 

3.1. Introduction

3.2. Pure versus multi-component co-promotion deals

3.3. Pure co-promotion agreement structure

3.3.1. Example co-promotion agreements

3.3.1.a. Case study 1: Allergan – MAP Pharmaceuticals

3.3.1.b. Case study 2: Genzyme – Veracyte

3.4. Co-promotion rights as part of a wider alliance agreement

3.4.1. Example co-promotion option clauses

3.4.1.a. Case study 3: Takeda Pharmaceutical– Orexigen Therapeutics

3.4.1.b. Case study 4: Celgene – Acceleron Pharma

3.4.2. Example co-promotion right clauses

3.4.2.a. Case study 5: Takeda – Orexigen

3.4.2.b. Case study 6: Abbvie – Receptos

3.5. Embedded co-promotion rights enabling third party engagement

3.5.1. Example co-promotion clauses enabling third party engagement

3.5.1.a. Case study 7: Astellas – Ambit Biosciences

 

Chapter 4 – Overview of co-marketing deal structure

 

4.1. Introduction

4.2. Co-marketing agreement structure

4.2.1. Example co-marketing agreements

4.2.1.a. Case study 8: AstraZeneca –Ironwood Pharmaceuticals

4.3. Co-marketing rights as part of a wider alliance agreement

4.3.1. Example co-marketing right clauses

4.3.1.a. Case study 9: Lundbeck – Myriad Genetics

 

Chapter 5 – Leading co-promotion and co-marketing deals

 

5.1. Introduction

5.2. Top co-promotion and co-marketing deals by value

 

Chapter 6 – Top 25 most active co-promotion and co-marketing dealmakers

 

6.1. Introduction

6.2. Top 25 most active co-promotion and co-marketing dealmakers

 

Chapter 7 – Co-promotion and co-marketing agreement contracts directory 2014 - 2021

 

7.1. Introduction

7.2. Co-promotion and co-marketing deals with contracts 2014 to 2021

 

Appendices

 

Appendix 1 – Co-promotion and co-marketing deals by company A-Z

Appendix 2 – Co-promotion and co-marketing deals by stage of development

Appendix 3 – Co-promotion and co-marketing deals by deal type

Appendix 4 – Co-promotion and co-marketing deals by therapy area

Appendix 5 – Co-promotion and co-marketing deals by technology type

Appendix 6 –Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements      

Recent report titles from Current Partnering

 

TABLE OF FIGURES

 

Figure 1: Definition of co-promotion and co-marketing

Figure 2: Trends in co-promotion and co-marketing deal announcements, 2014 to 2021

Figure 3: Co-promotion and co-marketing deals signed at each phase of development, 2014 to 2021

Figure 4: Co-promotion and co-marketing deals by industry sector, 2014 to 2021

Figure 5: Co-promotion and co-marketing deals by therapy area, 2014 to 2021

Figure 6: Co-promotion and co-marketing deals by technology type, 2014 to 2021

Figure 7: Top 25 most active co-promotion and co-marketing dealmakers, 2014 to 2021

Figure 8: Situations where co-marketing can prove useful

Figure 9: Key components of a pure co-promotion deal

Figure 10: Key components of a multi-component co-promotion deal

Figure 11: Example deals where co-promotion options have been actively exercised, since 2000

Figure 12: Issues in implementing co-promotion agreements

Figure 13: Co-promotion agreements – what should a contract include?

Figure 14: Components of the co-promotion deal structure

Figure 15: Components of the co-marketing deal structure

Figure 16: Top co-promotion and co-marketing deals by value since 2014

Figure 17: Most active co-promotion and co-marketing dealmakers 2014 to 2021

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3D Medicines, 10X Genomics, Abaxis, Abbvie, Abveris, Accent Therapeutics, Accinov, Accuray, ACEA Biosciences, Acelrx Pharmaceuticals, Acerus, AC Immune, ACIST Medical Systems, Adaptimmune, Advaita, Advanced Analytical Technologies, Advanced Cell Diagnostics, AEterna Zentaris, Affibody, Agena Bioscience, Agilent Technologies, Agios Pharmaceuticals, AGTC, AiLife Diagnostics, AirXpanders, Ajinomoto, Albany Molecular Research, Alector, Alexion Pharmaceuticals, Alfasigma, ALK-Abello, Allegis Holdings, Allergan, Almirall, Alnylam Pharmaceuticals, Alphaeon, Alphazyme, Amarin, Amgen, AmpTec, AMRA, AMRA Medical, Andrew Alliance, Appistry, Applied DNA Sciences, Applied Spectral Imaging, Aratana Therapeutics, ArcherDX, Arcis Biotechnology, Arcturus Therapeutics, Arcus Biosciences, Ardelyx, argenx, Argonaut Manufacturing Services, Aries Pharmaceuticals, Arkema, Armune Bioscience, ArQule, Arrowhead Pharmaceuticals, Asahi Kasei, Ascend Therapeutics, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Automated Systems of Tacoma, Avid Bioservices, Axcend, Aytu BioScience, Aziyo Biologics, Basilea Pharmaceutica, Bausch & Lomb, Baxalta, Bayer, B Braun, BD Biosciences, BeiGene, Belintra, Berlin Chemie, BGI, BGI Americas, BioAge Labs, Biochrom, Biocrates, Biodextris, BioDiscovery, Biogen, Biognosys, Biological Industries, BioNano Genomics, BioNTech, BioTek Instruments, Bioverativ, Blake Insomnia Therapeutics, Blanchette Rockefeller Neurosciences Institute, Bluebird Bio, Blueprint Medicines, Boehringer Ingelheim, BOWA Medical, BrainLAB, Bristol-Myers Squibb, Brooks Life Science Systems, Bruker, Burning Rock, Cambrooke Therapeutics, Cardiome Pharma, Catalent, CC Pharma, Celgene, Cellectricon, Cellenion, Cellular Dynamics International, Cellular Research, Centogene, Cevec Pharmaceuticals, Charleston Laboratories, Chromocell, Cipher Pharmaceuticals, Cisbio Bioassays, Clarify Medical, Clearbridge Biomedics, ClinicalRM, CloudHealth Genomics, COBO Technologies, Codexis, CompleWare, Concordia Pharmaceuticals, Consortia Health, CorTechs Labs, CRISPR Therapeutics, CrossBay Medical, Crown Bioscience, CSL, CStone Pharmaceuticals, Cumberland Pharmaceuticals, CureVac, Curio Genomics, Cypher Genomics, Cytokinetics, CytomX Therapeutics, CytoSorbents, Daiichi Sankyo, DARA BioSciences, Denali Therapeutics, DePuy, DexCom, Diabetes Tools, Dicerna Pharmaceuticals, DirectView Security Systems, Domainex, Dova Pharmaceuticals, Dovetail Genomics, Dynavax Technologies, Eagle Genomics, Eagle Pharmaceuticals, EA Pharma, EarlySense, eFFECTOR Therapeutics, Egalet, Eigen, Eisai, Elanco, Elekta, Eli Lilly, Elucidata, EMD Serono, Empatica, Entellus Medical, Enterome Bioscience, EOS Imaging, Epicypher, Epizyme, EPS International, Eton Pharmaceuticals, Eurofins Genomics, Everledger, Evosep, eWellness Healthcare, Exact Sciences, Fabric Genomics, Fate Therapeutics, Ferring Pharmaceuticals, FlowJo, Fortelinea Software Systems, Fresenius Medical Care, FUJIFILM SonoSite, Fusion Pharmaceuticals, G1 Therapeutics, Galapagos, GE Healthcare, GenDx, Genentech, Genetron Health, Genialis, Genmab, Genomoncology, Genoox, Genosity, Genzyme, George Clinical, Geron, Gilead Sciences, Gilson, GlaxoSmithKline, Glenmark Pharmaceuticals, Goldfinch Bio, Greiner Bio-One, Guerbet, Guohong Guokang (Beijing) Health Technology Development, H3 Biomedicine, HalioDx, Halyard Health, Hanmi Pharmaceutical, Harbour Antibodies, HarkerBIO, HD Biosciences, HeartGenetics, Helsinn Therapeutics, Henkel, Hepregen, Herman Miller-Nemschoff, High Beauty, Hitachi Medical Systems Europe, Hormosan Pharma GmbH, Human Longevity, Iagnosis, IBA, IBM Watson Health, Icagen, Iconic Therapeutics, IDbyDNA, Idorsia, Igentify, Illumina, Immatics Biotechnologies, ImmunityBio, ImmunoGen, Immunomedics, Incyte, Indegene Lifesystems, Innara Health, Innate Pharma, Innova Biosciences, Innovent Biologics, Inscopix, Insitro, InSphero, Inspirion Delivery Sciences, Intabio, Integrated DNA Technologies, IROA Technologies, Ironwood Pharmaceuticals, Janssen Biotech, Janssen Pharmaceuticals, Jiangsu Alphamab, Jiangsu Chia Tai Tianqing Pharmaceutical, Jointpoint, Joylux, K2M, Kadmon Pharmaceuticals, Kailos Genetics, Kaleo, Kerma Medical Products, Konica Minolta, Kowa Pharmaceuticals America, KSQ Therapeutics, KVP International, Kyorin Pharmaceutical, Kyowa Hakko Kirin, L1 Systems, Leica Biosystems, Leica Microsystems, LEO Pharma, Lexicon Pharmaceuticals, Lexington Medical, LI Path, Lord Global, Loxo Oncology, Lumos Pharma, Luqa Pharmaceuticals, Luxcel Biosciences, Lygos, Macherey-Nagel, Macrogenics, Malvern Instruments, MannKind Biopharmaceuticals, Mazor Robotics, MDxHealth, MedHelp, Medical Enterprises Distribution, Medicines360, Medigus, MedImmune, Medis, Medovate, Medtronic, Meiji Seika, MEI Pharma, Menarini, Menarini Silicon Biosystems, Merck and Co, Merck KGaA, Mesoblast, Metavant, MGC Diagnostics, MGI Tech, Microsaic Systems, Microsoft, Midatech, Miltenyi Biotec, Mission Pharmacal, Mitsubishi Chemical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Moderna Therapeutics, Molnlycke Health Care, Momenta Pharmaceuticals, Morphic Therapeutic, MorphoSys, MSD, Multispan, MYOS, Myovant Sciences, Myriad Genetics, N-of-One, Nanion, Nano3D Biosciences, NanoString Technologies, NantKwest, NantPharma, Napo Pharmaceuticals, Ncardia, Neurexpert, Neurocrine Biosciences, Neurotrope BioScience, Newomics, New York Center for Nanomedicine Research, Nexa3D, NGM Biopharmaceuticals, Norgenix Pharmaceuticals, Novartis, Noven Pharmaceuticals, Novogene, Novo Nordisk, Nrgene, Nucleai, Nurix, ODI Pharma, Ohio Clinical Trials Collaborative, Olympus Medical Systems, OncoSec Medical, Ono Pharmaceutical, OpGen, OptiNose, Orapharma, OraSure Technologies, ORFLO Technologies, Orion, Ortho-Clinical Diagnostics, Osteopore International, Otonomy, Otsuka, Oxford BioMedica, Pacific BioScience of California, Pacific Biosciences, PacificGMP, Pacira Pharmaceuticals, Paragon Bioservices, Pfizer, Pharmaceutics International, Phenomenex, Picometrics Technologies, PierianDx, Pieris, Piramal, Pivot Pharmaceuticals, PositiveID, Poxel, Precipio Diagnostics, Precision BioSciences, Predicine, Pressure BioSciences, Protagonist Therapeutics, Protea Biosciences, Protean BioDiagnostics, Protein Metrics, Proteos, ProTom International, PSI (Population Services International), Purdue Pharma, PureHoney Technologies, Pure Pharmaceuticals, Qiagen, Quanta, Radformation, Rainbow Scientific, RainDance Technologies, RayBiotech, RaySearch Laboratories, Reaction Biology, RedHill Biopharma, Regulus Therapeutics, Relay Therapeutics, Resonant Specific Technologies, Revolution Medicines, Rigel Pharmaceuticals, Roche, Roche Diagnostics, Roivant Sciences, Rosetta Genomics, Rubicon Genomics, SAFC, Sage Therapeutics, Sajo Consulting, Salix Pharmaceuticals, Sangamo BioSciences, Sanofi, Sanofi-Aventis, Santen Pharmaceutical, Sarepta Therapeutics, Sato Pharmaceutical, Sciex, Seattle Genetics, Senshinkai Eye Institute, Seracare Life Sciences, Seren Pharmaceuticals, Shimadzu, Shionogi, Silicon Biosystems, Simcere Pharmaceuticals, Sirtex Medical, Sividon Diagnostics, SK Biopharmaceuticals, Solid Biosciences, Sorrento Therapeutics, SoTAX, Spectrum Pharmaceuticals, SPI Pharma, SpiroChem, Staar Surgical Co, Stealth Therapeutics, StrideBio, Stryker, STU, Suneva Medical, Sunovion Pharmaceuticals, Sun Pharmaceutical, SurGenTec, Swift Biosciences, Swixx Biopharma, Synaptive Medical, Taiho, Taisho Pharmaceutical, Takeda Pharmaceutical, Tango Therapeutics, Tecan, Teijin, Terumo BCT, Tetraphase Pharmaceuticals, TGR BioSciences, The Fleury Group, Theravance, Thermo Fisher Scientific, Threshold Pharmaceuticals, Tilak Healthcare, Tilray, Tissue Analytics, Titan Pharmaceuticals, TOMI Environmental Solutions, Tracey Technologies, TRACON Pharmaceuticals, Trovita Health Science, TTP LabTech, Twist Bioscience, Tyme Technologies, UCB, Ultragenyx Pharmaceuticals, Uni-Bio Science, Universal Cells, Urovant Sciences, US WorldMeds, Valeant Pharmaceuticals, VCA Antech, Veracyte, Verity Pharmaceuticals, Vertex Pharmaceuticals, Vertice Pharma, Vida Diagnostics, Vifor Pharma, Visiopharm, ViveBio, Vivid Medical, Waters Corporation, WAVE Life Sciences, White Labs, Wyatt Technology, XCellCure, Xellia Pharmaceuticals, Xencor, Xoran Technologies, ZAI Laboratory, Ziath, Zymeworks

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.